SCHEMBL6844207

SCHEMBL6844207

CC1(C)OC[C@H](CNO)O1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.56
NAMPT P43490 3/20 0.37
ALDH1A1 P00352 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
TMEM97 Q5BJF2 2/20 0.35
SIGMAR1 Q99720 2/20 0.35
CHRM2 P08172 3/20 0.33
CHRM4 P08173 3/20 0.33
CHRM5 P08912 3/20 0.33
CHRM3 P20309 3/20 0.33
CHRM1 P11229 2/20 0.31
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
TP53 P04637 1/20 0.31
CYP3A4 P08684 1/20 0.31
MAPT P10636 1/20 0.31
PKM P14618 1/20 0.31
HPGD P15428 1/20 0.31
ALOX15 P16050 1/20 0.31
MAPK1 P28482 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3500787 1.00 CA2 (0.56) CA2NAMPTALDH1A1NPSR1TMEM97
SCHEMBL5990159 1.00 CA2 (0.56) CA2NAMPTALDH1A1NPSR1TMEM97
SCHEMBL20689800 0.83 CA2 (0.59) CA2NAMPTALDH1A1NPSR1TMEM97
SCHEMBL4423252 0.81 CA2 (0.58) CA2NAMPTALDH1A1NPSR1TMEM97
SCHEMBL12786547 0.81 CA2 (0.58) CA2NAMPTALDH1A1NPSR1TMEM97
SCHEMBL12786551 0.81 CA2 (0.58) CA2NAMPTALDH1A1NPSR1TMEM97
SCHEMBL10433600 0.80 CA2 (0.45) CA2NAMPTALDH1A1NPSR1TMEM97
SCHEMBL6712276 0.80 CA2 (0.38) CA2
SCHEMBL24465140 0.79 CA2 (0.56) CA2NAMPTALDH1A1NPSR1TMEM97
SCHEMBL1760212 0.79 CA2 (0.61) CA2NAMPTALDH1A1NPSR1TMEM97

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101065358-A 3-arylamino pyridine derivatives APPLIED RESEARCH SYSTEMS (AN) 2007-10-31 CN disclosed
US-6770778-B2 MAP KINASE INHIBITORS; ANTICARCINOGENIC AGENTS; RESTENOSIS, PSORIASIS, AND ATHEROSCLEROSIS TREATMENT; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS PFIZER INC 2004-08-03 US disclosed
US-20030232889-A1 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters WARNET-LAMBERT COMPANY LLC 2003-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232889-A1 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters AADAC, EGLN3, HCAR2 CA2 338/4885NAMPT 152/4885ALDH1A1 363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.